CKI27 is out-licensed from Chugai to Verastem Oncology, a
'Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study' https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30464-2/fulltext
The study was an investigator-initiated study in patients with RAS/RAF-mutated solid tumors and multiple myeloma, conducted at
The recommended dosage were determined to be 4 mg/day twice weekly in the dose escalation part. In the subsequent basket expansion part, 7 of 26 evaluable patients (26.9%) achieved objective responses. All patients with KRAS-mutation had non-G12C mutations. The most common treatment-related adverse events occurred as grade 3 or higher based on CTCAE v4.0 (the Common Terminology Criteria for Adverse Events provided by the
CKI27 (VS-6766) is a new oral RAF/MEK inhibitor. Under the global licensing agreement concluded in January, 2020, clinical development of CKI27 is being conducted by Verastem Oncology under the name of VS-6766.
Chugai, which aims at becoming a top innovator in the healthcare industry, continues to pursue science and proprietary technology and promote open innovation including collaboration with academia, to contribute for patients across the world through innovative drugs.
Contact:
Tel: +81-3-3273-0881
Email: pr@chugai-pharm.co.jp
(C) 2020 Electronic News Publishing, source